Director, HTA, Value & Evidence (HV&E), I&I / Brepocitinib (Med Rheum)

Pfizer•New York City, NY

2d•Hybrid

About The Position

The Director, Value & Evidence – Brepocitinib will support the strategic goals of the Inflammation & Immunology Business Unit by driving optimal launch and patient access for Brepocitinib through the generation, integration, and translation of robust value and evidence. This role directly impacts Pfizer’s ability to achieve global access and reimbursement objectives by providing strategic leadership and execution of Health Technology Assessment, Value & Evidence (HV&E) activities that demonstrate the value of Brepocitinib across its lifecycle, including launch and post-launch phases. This role is part of a collaborative Brepocitinib HV&E team structure, working alongside existing team members to jointly deliver launch and lifecycle evidence. The Director will partner with the Brepocitinib HV&E team to develop and execute the global value and evidence generation strategy for Brepocitinib, including supporting oversight of evidence generation activities and dissemination of technical deliverables in close partnership with GASP, cross-functional and alliance teams. This position will function with a one "Global Value & Access” mindset and work in a closely aligned manner with GASP, Medical, Clinical, Value & Access, Commercial, and alliance partners to ensure a single, coordinated view on evidence strategy and delivery for Brepocitinib globally.

Requirements

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Graduate degree required (e.g. MSc, MPH, PhD)
7+ years of experience with MSc/MPH/MBA degree; 5+ years with PharmD/PhD in HEOR or relevant related fields (health economics, epidemiology, health services research, or other research-focused public health field)
Demonstrated depth of understanding of fundamental health services research methods and tools, including: Health economic modeling Cost-effectiveness and budget impact analyses Indirect treatment comparisons Patient-reported outcomes and quality-of-life measures Real-world evidence study design and analysis
Proven ability to manage multiple complex projects involving significant budget, competing timelines, and rapidly shifting priorities.
Demonstrated ability to influence and collaborate effectively in a matrix organization , managing through influence rather than authority.
Demonstrated ability to work effectively in co-ownership models within matrix organizations.
Strong execution mindset with a track record of delivering high-quality outputs efficiently.
Excellent oral and written English communication skills.

Nice To Haves

Experience working with HTA organizations (e.g., NICE, CADTH, ICER, PBAC, and other reimbursement bodies).
Experience supporting late-stage or launch assets .
Knowledge and experience in Inflammation & Immunology therapeutic areas, including rheumatology.
Prior experience working in alliance or co-development environments .
Launch experience strongly preferred.

Responsibilities

Drive, together with the Brepocitinib HV&E team, the development and execution of the global value and evidence generation strategy to support the value of Brepocitinib in close partnership with the cross-functional matrix team.
Support and coordinate, together with the Brepocitinib HV&E colleagues, input from global and country teams on evidence needs and ensure alignment and integration into a coherent global evidence strategy across launch and lifecycle.
Lead the review, interpretation, and translation of clinical trial outputs , including Clinical Study Reports (CSRs), to identify HEOR-relevant insights, evidence gaps, and post-hoc analytical needs.
Working as part of the Brepocitinib HV&E team, contribute to the design, execution, and oversight of HV&E studies, including: Cost-effectiveness and budget impact models Indirect treatment comparisons / network meta-analyses Systematic literature reviews (clinical, economic, humanistic, epidemiology) Patient-reported outcome and quality-of-life evidence generation Real-world evidence studies (e.g., treatment patterns, burden of disease, epidemiology, real-world effectiveness)
Develop and maintain global value narratives and evidence deliverables (e.g., Global Value Dossiers .. etc) to support HTA submissions and payer decision-making.
Engage with cross-functional clinical development teams to ensure the evidence strategy is optimally positioned to support rapid and broad access upon launch.
Collaborate closely with alliance partners, jointly representing the Brepocitinib HV&E team, to align on evidence strategy, roles, and execution responsibilities.
Develop strategic external partnerships and research collaborations with key experts, HTA stakeholders, and academic institutions as appropriate.
Manage HV&E budgets and vendor relationships effectively.
Ensure all activities are conducted in compliance with Pfizer SOPs, governance, and regulatory requirements.

Benefits

In addition, this position is eligible for participation in Pfizer’s Global Performance Plan with a bonus target of 20.0% of the base salary and eligibility to participate in our share based long term incentive program.
We offer comprehensive and generous benefits and programs to help our colleagues lead healthy lives and to support each of life’s moments.
Benefits offered include a 401(k) plan with Pfizer Matching Contributions and an additional Pfizer Retirement Savings Contribution, paid vacation, holiday and personal days, paid caregiver/parental and medical leave, and health benefits to include medical, prescription drug, dental and vision coverage.

Stand Out From the Crowd

Upload your resume and get instant feedback on how well it matches this job.

Upload and Match Resume